Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient

Patent metadata

Field	Value
Publication number	US-11642350-B2
Application number	US-201816495350-A
Country	US
Kind code	B2
Filing date	Mar 22, 2018
Priority date	Mar 23, 2017
Publication date	May 9, 2023
Grant date	May 9, 2023

Abstract

The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.

First claim

The invention claimed is:

1. A method for treating or preventing myopia, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of tiotropium or a pharmaceutically acceptable salt and/or hydrate thereof as a sole active ingredient, and sterile purified water as a sole solvent, wherein
the concentration of tiotropium or the salt and/or hydrate thereof in the pharmaceutical composition is from about 0.0001% to about 0.01% (w/v),
the pharmaceutical composition is formulated as an eyedrop, and
the administration does not cause substantial mydriatic action.

2. The method of claim 1 , wherein the administration is an ocular topical administration.

3. The method of claim 2 , wherein the ocular topical administration is instillation administration.

4. The method of claim 1 , wherein the tiotropium or a pharmaceutically acceptable salt and/or hydrate thereof is tiotropium bromide hydrate.

5. A method for preventing myopia progression, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of tiotropium or a pharmaceutically acceptable salt and/or hydrate thereof as a sole active ingredient, and sterile purified water as a sole solvent, wherein
the concentration of tiotropium or the salt and/or hydrate thereof in the pharmaceutical composition is from about 0.0001% to about 0.01% (w/v),
the pharmaceutical composition is formulated as an eyedrop, and
the administration does not cause substantial mydriatic action.

6. The method of claim 5 , wherein the administration is an ocular topical administration.

7. The method of claim 6 , wherein the ocular topical administration is instillation administration.

8. The method of claim 5 , wherein the tiotropium or a pharmaceutically acceptable salt and/or hydrate thereof is tiotropium bromide hydrate.

9. A method for suppressing axial length elongation in a subject, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of tiotropium or a pharmaceutically acceptable salt and/or hydrate thereof as a sole active ingredient, and sterile purified water as a sole solvent, wherein
the concentration of tiotropium or the salt and/or hydrate thereof in the pharmaceutical composition is from about 0.0001% to about 0.01% (w/v),
the pharmaceutical composition is formulated as an eyedrop, and
the administration does not cause substantial mydriatic action.

Assignees

• Singapore Health Serv Pte Ltd
• Santen Pharmaceutical Co Ltd

Inventors

• Tan Tiang Hwee Donald
• Beuerman Roger Wilmer
• Saw Seang-Mei
• Upadhyay Aradhana
• Kato Masatomo
• Inaba Takaaki

Classifications

• A61P27/10

  for accommodation disorders, e.g. myopia · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

• A61K31/5386 Primary

  spiro-condensed or forming part of bridged ring systems · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K31/439 Primary

  the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46) · CPC title